Barclays Maintains Overweight on Revolution Medicines, Raises Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson has maintained an Overweight rating on Revolution Medicines (NASDAQ:RVMD) and increased the price target from $54 to $60.
September 27, 2024 | 6:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays has reaffirmed its Overweight rating on Revolution Medicines and increased the price target to $60, indicating confidence in the company's future performance.
The increase in price target from $54 to $60 by Barclays suggests a positive outlook on Revolution Medicines' future performance. The Overweight rating indicates that the analyst expects the stock to outperform its peers. This is likely to have a positive short-term impact on RVMD's stock price as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100